Savara (SVRA) Preferred Dividend Payments (2016 - 2017)
Savara (SVRA) reported Preferred Dividend Payments of $554000.0 for Q2 2017, up 27600.0% year-over-year from N/an in Q2 2016, and up 2208.33% quarter-over-quarter from $24000.0 in Q1 2017.
Savara (SVRA) Preferred Dividend Payments (2016 - 2017) Analysis & Trends
Savara (SVRA) has 2 years of Preferred Dividend Payments data on file, last reported at $554000.0 in Q2 2017.
- Preferred Dividend Payments for Q2 2017 came in at $554000.0, up 27600.0% year-over-year; the trailing twelve-month figure through Dec 2017 was $578000.0 (changed N/A YoY), and the FY2017 annual result was $578000.0, up 514.89% from the prior year.
- Preferred Dividend Payments climbed to $554000.0 in Q2 2017 per SVRA's latest filing, from $24000.0 in the prior quarter.
- Over five years, Preferred Dividend Payments peaked at $554000.0 in Q2 2017 and troughed at $2000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 554,000.00 |
| Mar 31, 2017 | 24,000.00 |
| Dec 31, 2016 | 24,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Jun 30, 2016 | 2,000.00 |